A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Top Cited Papers
- 18 February 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (7), 619-629
- https://doi.org/10.1056/nejmoa2031304
Abstract
Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient’s clinical status 30 days after the intervention, as measured on a six-point ordinal scale ranging from total recovery to death. A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200]. No patients were lost to follow-up. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83 (95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups. No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535.)Keywords
Funding Information
- Hospital Privado de la Comunidad
- Hospital Zonal Ramón Carrillo de Bariloche
- Hospital Privado de Córdoba
- Sanatorio Británico de Rosario
- Sanatorio Trinidad de Palermo
- Clínica Santa Isabel
- Hospital Italiano de Buenos Aires
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Gobierno de la Ciudad de Buenos Aires
- Swiss Medical Group
- Hospital Universitario Austral
This publication has 19 references indexed in Scilit:
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Evaluation of Convalescent Plasma for Ebola Virus Disease in GuineaThe New England Journal of Medicine, 2016
- Research Electronic Data Capture (REDCap) - planning, collecting and managing data for clinical and translational researchBMC Bioinformatics, 2012
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionThe New England Journal of Medicine, 2007
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Sample size calculations for ordered categorical dataStatistics in Medicine, 1993
- EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROMEThe Lancet, 1979